{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:21:55Z","timestamp":1747196515225,"version":"3.40.5"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Our goal was to assess the impact of prior cancer history on the prognosis of extranodal NK\/T-cell lymphoma (ENKTCL). We searched the SEER database to retrospectively enroll patients with ENKTCL. The effects of cancer history on overall survival (OS) and disease-specific survival (DSS) were analyzed using the Cox model. A total of 691 patients were included, of whom 54 (7.8%) had prior histories of cancer. The most common solid malignancy was bone\/soft tissue sarcoma. Most secondary ENKTCL cases occurred within 5\u20139 years following the first cancer diagnosis. Radiotherapy and chemotherapy had been administered to 45 and 40 patients, respectively, to treat their previous malignancies. Prior cancer history had little impact on DSS; however, the presence of prior solid cancer history, latency period of 10+ years, and prior administration of radiotherapy or chemotherapy significantly decreased OS. Prior cancer history had no effect on DSS, but survival compromised OS under specific circumstances.<\/jats:p>","DOI":"10.1371\/journal.pone.0311094","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:30:33Z","timestamp":1729099833000},"page":"e0311094","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of prior cancer history on the prognosis of extranodal NK\/T-cell lymphoma"],"prefix":"10.1371","volume":"19","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-0837","authenticated-orcid":true,"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"pone.0311094.ref001","doi-asserted-by":"crossref","first-page":"103237","DOI":"10.1016\/j.critrevonc.2021.103237","article-title":"Extranodal NK\/T cell lymphoma, nasal type: An updated overview.","volume":"159","author":"C S\u00e1nchez-Romero","year":"2021","journal-title":"Crit Rev Oncol Hematol."},{"key":"pone.0311094.ref002","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-022-03434-0","article-title":"Extranodal T- and NK-cell lymphomas.","volume":"482","author":"L de Leval","year":"2023","journal-title":"Virchows Arch."},{"key":"pone.0311094.ref003","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","article-title":"NK-\/T-cell lymphomas.","volume":"35","author":"H Wang","year":"2021","journal-title":"Leukemia"},{"key":"pone.0311094.ref004","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hon.2944","article-title":"Review on natural killer\/T-cell lymphoma.","volume":"41","author":"X He","year":"2023","journal-title":"Hematol Oncol."},{"key":"pone.0311094.ref005","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ejh.13038","article-title":"Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools","volume":"100","author":"H Kurt","year":"2018","journal-title":"Eur J Haematol"},{"key":"pone.0311094.ref006","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2018.1515944","article-title":"Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin","volume":"60","author":"T Badar","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"pone.0311094.ref007","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/10428194.2019.1663418","article-title":"De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era","volume":"61","author":"B Hu","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"pone.0311094.ref008","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.","volume":"31","author":"BK Link","year":"2013","journal-title":"J Clin Oncol"},{"key":"pone.0311094.ref009","doi-asserted-by":"crossref","first-page":"1088685","DOI":"10.3389\/fimmu.2023.1088685","article-title":"Treatment of extranodal NK\/T-cell lymphoma: From past to future.","volume":"14","author":"Z Yan","year":"2023","journal-title":"Front Immunol."},{"key":"pone.0311094.ref010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","article-title":"How we treat NK\/T-cell lymphomas.","volume":"15","author":"E Tse","year":"2022","journal-title":"J Hematol Oncol"},{"key":"pone.0311094.ref011","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1002\/cam4.4036","article-title":"Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer","volume":"10","author":"SL Pruitt","year":"2021","journal-title":"Cancer Med"},{"key":"pone.0311094.ref012","first-page":"6116658","article-title":"Effect of previous cancer history on survival of patients with different subtypes of breast cancer","volume":"2022","author":"W Lin","year":"2022","journal-title":"Biomed Res Int"},{"key":"pone.0311094.ref013","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.ejso.2022.06.022","article-title":"Impact of a previous cancer history on the overall survival of patients with primary gastric cancer: A SEER population-based study","volume":"48","author":"Y Chen","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"pone.0311094.ref014","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4143\/crt.2019.202","article-title":"Secondary squamous cell carcinoma of the oral cavity after nasopharyngeal carcinoma","volume":"52","author":"L Dai","year":"2020","journal-title":"Cancer Res Treat"},{"key":"pone.0311094.ref015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","article-title":"Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study","volume":"30","author":"JD Brewer","year":"2012","journal-title":"J Clin Oncol"},{"first-page":"9","volume-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000, NIH Publ No 05\u20135302.","author":"RE Curtis","key":"pone.0311094.ref016"},{"key":"pone.0311094.ref017","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1177\/1740774512456453","article-title":"Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment","volume":"9","author":"M Filion","year":"2012","journal-title":"Clin Trials (London, England)."},{"key":"pone.0311094.ref018","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1186\/s12885-020-07634-2","article-title":"Impact of prior cancer history on the survival of patients with larynx cancer","volume":"20","author":"K Zhu","year":"2020","journal-title":"BMC Cancer"},{"key":"pone.0311094.ref019","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.lungcan.2018.11.040","article-title":"Variable impact of prior cancer history on the survival of lung cancer patients","volume":"127","author":"AF Monsalve","year":"2019","journal-title":"Lung Cancer"},{"key":"pone.0311094.ref020","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ijc.31543","article-title":"Impact of prior cancer history on the overall survival of patients newly diagnosed with cancer: A pan-cancer analysis of the SEER database","volume":"143","author":"H Zhou","year":"2018","journal-title":"Int J Cancer"},{"key":"pone.0311094.ref021","doi-asserted-by":"crossref","first-page":"djv002","DOI":"10.1093\/jnci\/djv002","article-title":"Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual","volume":"107","author":"AL Laccetti","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"pone.0311094.ref022","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2016.12.024","article-title":"Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma","volume":"144","author":"SR Pierce","year":"2017","journal-title":"Gynecol Oncol"},{"key":"pone.0311094.ref023","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1007\/s00405-022-07444-1","article-title":"Prior cancer history predicts the worse survival of patients with nasopharyngeal carcinoma","volume":"279","author":"CF Yeh","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"pone.0311094.ref024","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/s41598-020-58134-z","article-title":"Secondary cancer risk after radiation therapy for breast cancer with different radiotherapy techniques","volume":"10","author":"Q Zhang","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0311094.ref025","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MOU.0000000000000763","article-title":"Testosterone therapy and risk of breast cancer development: A systematic review","volume":"30","author":"A Ray","year":"2020","journal-title":"Curr Opin Urol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:30:41Z","timestamp":1729099841000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311094"}},"subtitle":[],"editor":[{"given":"Niraj","family":"Babu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311094","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}